44 results about "Atp level" patented technology

Methods and compositions for resuscitating, storing, and preserving functional integrity of organs and tissues. Metabolic function is maintained by sustaining ATP levels, mitochondrial function, cardiomyocyte contractility, prevention of acidosis, inhibition of induction of apoptosis, maintaining ionontrophy and lusiotrophy by regulating calcium, sodium, potassium and chloride ions.

Nonsymbiotic hemoglobins are broadly present across evolution; however, the function of these proteins is unknown. Cultured maize cells have been transformed to constitutively express a barley hemoglobin gene in either the sense (HB+) or antisense (HB−) orientation. Hemoglobin protein in the transformed cell lines was correspondingly higher or lower than in wild type cells under normal atmospheric conditions. Limiting oxygen availability, by placing the cells in a nitrogen atmosphere for 12 hours, had little effect on the energy status of cells constitutively expressing hemoglobin, but had a pronounced effect on both wild type and HB− cells, where ATP levels declined by 27% and 61% respectively. Energy charge was relatively unaffected by the treatment in HB+ and wild type cells, but was reduced from 0.91 to 0.73 in HB− cells suggesting that the latter were incapable of maintaining their energy status under the low oxygen regime. Similar results were observed with P. aeruginosa cells transformed with an Hb expression vector. It is suggested that nonsymbiotic hemoglobins act to maintain the energy status of cells in low oxygen environments and that they accomplish this effect by promoting glycolytic flux through NADH oxidation, resulting in increased substrate level phosphorylation. Nonsymbiotic hemoglobins are likely ancestors of an early form of hemoglobin that sequestered oxygen in low oxygen environments, providing a source of oxygen to oxidize NADH to provide ATP for cell growth and development. This in turn suggests that cells containing increased levels of Hb protein will survive longer under low oxygen tension or high energy demand.

This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X7 and A3 receptors on ganglion cells, by reducing levels of ATP released into the extracellular space of the retina and enhancing the conversion of released extracellular ATP into adenosine.

A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.

The present invention provides for a transgenic non-human animal whose cells contain a recombinant DNA sequence comprising a nerve tissue specific promoter operatively linked to a DNA sequence which encodes amyloid-beta peptide alcohol dehydrogenase (ABAD), and exhibits at least one phenotype from the group consisting of: overexpression of ABAD, elevated levels of basal ATP; protection from metabolic or ischemic stress.

The invention provides drugs used for treating atherosclerotic diseases such as carotid artery stenosis, lower extremity atherosclerotic occlusive disease, and coronary heart disease, and more specifically discloses applications of compound Szeto-Schiller-31 (SS-31) in preparing drugs or preparations used for treating atherosclerosis and related diseases, and belongs to the field of medicine, and more specifically belongs to the field of novel pharmaceutical applications of compounds. It is found via experiments that SS-31 is capable of reducing atherosclerosis degree, reducing mouse arterial ROS level obviously, reducing oxidative damage, increasing ATP level, reducing the content of macrophages at atherosclerotic plaques obviously, increasing the content of smooth muscle cells and the content of collagen at atherosclerotic plaques obviously, stabilizing atherosclerotic plaques, improving inflammation level obviously, and reducing expression of lipid intake protein at atherosclerotic plaques; and it is shown by results that SS-31 is capable of treating atherosclerosis and related diseases.

The invention discloses a technology for producing glutathione by fermenting saccharomyces cerevisiae and belongs to the field of industrial microbial fermentation. The technology for producing glutathione by fermenting saccharomyces cerevisiae comprises the following steps: utilizing an improved O-media fermentation medium to ferment for 16h, and then adding molasses and corn liquor at constant speed of 1.5g / L / h and 0.4g / L / h; after the cell density reaches a certain degree, adding a certain amount of KMnO4 slow-released grains and sodium citrate into the fermentation liquor; fermenting for 120h so that the cell wet weight in the fermentation liquor reaches up to 121.4g / L and the GSH accumulated volume reaches up to 5.78g / L. According to the invention, the cell density of the fermentation liquor is promoted through the improvement for the O-media fermentation medium and the flow adding of the molasses and corn liquor; the oxidative stress for yeast cells is maintained and meanwhile the influence thereof on the yeast growth is relieved through the addition of oxidized stimulant KMnO4 slow-released grains; intracellular ATP level is improved through the addition of the energy auxiliary matter sodium citrate, and finally, the accumulated volume of glutathione is obviously improved and the production cost is lowered.

Effective anticancer agents for use in treatment of particular cancers can be predicted by testing whether particular anticancer agents are effective in reducing the lactic acid production by sample cells removed from the particular cancerous tissue to be treated. Similarly, effective anticancer agents can be predicted by testing whether particular anticancer agents are effective in reducing ATP levels in sample cells removed from the particular cancerous tissue. A method of predicting anticancer agents that will be effective for use in treating a particular cancer includes the steps of obtaining a plurality of samples of the cancerous tissue to be treated and determining the capacity of a sample to produce lactic acid in both the presence and absence of a particular anticancer agent. Anticancer agents that most reduce the lactic acid production should be effective treatment agents. Similarly, anticancer agents that most reduce the presence of ATP in the sample cancer cells should be effective treatment agents.

The invention discloses a method for improving the acid stress resistance of candida glabrata, and belongs to the field of bioengineering. The method comprises the following steps: improving the candida glabrata, constructing a gene-deleted mutant strain Cgade12Delta, measuring the intracellular ATP level of the constructed strain, and determining the organic acid tolerance of the strain by a plate growth experiment and cellular activity analysis. After the deletion of the gene CgADE12 is found out, the intracellular ATP level of the strain under the stress of 0.2 percent acetic acid is lowered, the growth capability under the stress of acetic acid is improved, and the acetic acid tolerance is improved.

A method for evaluating the efficacy of a skin-cleansing composition comprises measuring an ATP level on a skin site after cleansing. A method for evaluating the condition of living skin comprises measuring an ATP level on a skin site. The ATP level may be monitored over time to determine a rate of change in the ATP level on the skin site.

The invention discloses a method for producing hydrogen by culturing hydrogen-producing microbes in a culture medium containing phosphate oils. Phosphate is added in a cellular environment to simultaneously promote rapid growth and rapid recovery of ATP, thus controlling the ATP level and oxidization-reduction potential in cells, and accelerating consumption of carbon source and the production efficiency and hydrogen. Additionally, the phosphate can be recycled in the culture system without contaminating the environment. By using the method of the invention, the hydrogen production rate is improved by more than three times, the sugar utilization rate is improved by five times, and the hydrogen transformation efficiency is remarkably improved.

The present invention relates to methods of altering the competence of a dendrite and / or the viability of a neuron. The present invention also provides methods of altering the ATP levels in a neuron, methods of isolating at least one protein of a mitochondrial permeability transition pore complex, methods of introducing an RNA into a neuron, methods of translating an RNA in a dendrite, methods of monitoring risk of neurodegeneration of a neuron, and methods of treatment for neurodegenerative diseases.

The invention provides a method for improving the quality and efficiency of in vitro maturation of an oocyte, which includes the step of changing an in vitro maturation fluid at least once during in vitro maturation, and further comprising adding an amount of FGF to the in vitro maturation fluid. The oocyte prepared by the method of the invention has remarkably improved nuclear maturation efficiency and cytoplasmic maturation efficiency, the MII oocyte is up to 95%, the proportion of oocytes with normal distribution of cortical granules and mitochondria, the levels of glutathione and ATP are significantly higher than those of the normal maturation group; Adding a certain amount of FGF to IVM can further improve the maturation quality and efficiency of oocytes. After in vitro fertilization,the in vitro fertilization efficiency of the oocytes prepared by the method of the invention is significantly higher than that of the normal maturation group, which is embodied in higher cleavage rate, blastocyst rate and more blastocyst cells, and has great application value.

A peptide of formula: R1-X1-X2-X3-X4-X5-R2, wherein X1 is T; S2 is L; X3 is K; X4 is T, S, K, R or no amino acid; X5 is V, A, Y, M or no amino acid; R1 represents a primary amine function of the N-terminal amino acid; and R2 represents a hydroxyl function of the C-terminal amino acid, is capable of activating cytochrome C. The peptide can be included in cosmetic and pharmaceutical compositions intended to stimulate the functions of the mitochondria and increase intracellular ATP levels. Such compositions are useful to help protect the skin from external aggression, reduce and treat skin damage caused by UV radiation and combat cutaneous signs of aging.

Described herein is a method to increase ethanol yield during alcoholic fermentation by expression a truncated versions of the Saccharomyces cerevisiae PHO8 gene coding for vacuolar or cytosolic form of alkaline phosphatase, which expression lowers biomass accumulation while diverting greater carbon to ethanol production. Also described are as nucleic acid sequences and vectors for expression of the PHO8 gene and strains carrying the same. Strains containing intact PHO8 gene encoding vacuolar form of alkaline phosphatase, had slightly lower intracellular ATP levels with insignificant changes in biomass accumulation and up to 13% increase in ethanol production.

An object of the present invention is directed to a method for assaying the severity of an illness in real time and is to provide a testing method capable of assessing the severity of an illness in more detail than the conventional APACHE II and SOFA scores. The established method can accurately measure an ATP level in a sample, thereby accurately and quickly deducing the “state of intracellular energy required for living organisms” from the ATP level, and by extension, determining the severity of an illness. The present invention further provides a novel biomarker ATP-lactate energy risk score (A-LES) value that is capable of determining the severity of an illness by the reevaluation, with the ATP concentration as an index (specifically, on the basis of a lactic acid level (mM) / ATP concentration (mM) ratio), of the level of lactic acid that accumulates in the sample due to the breakdown of in vivo metabolic balance accompanied by the increased severity of the illness. The present invention also provides a novel biomarker ATP-ketone energy risk score (A-KES) value that is capable of determining the severity of an illness by the reevaluation of a ketone body level in the sample with the ATP concentration as an index (specifically, on the basis of a ketone body level (mM) / ATP concentration (mM) ratio).

Provided herein are methods and compositions for resuscitating, storing, and preserving the functional integrity of organs and tissues at ambient temperatures for up to 24 hours. Metabolic function ismaintained by sustaining ATP levels, mitochondrial function, prevention of edema, and by regulating calcium, sodium, potassium, magnesium, and chloride ions.

The invention provides a pharmaceutical composition and application of the composition in prevention or treatment of neurodegenerative diseases. The pharmaceutical composition comprises sacha inchi oil and / or lipoic acid, and is used for at least one of the following functions: preventing and / or treating neurodegenerative diseases, increasing the survival rate of nerve cells, reducing apoptosis ofnerve cells, increasing the mitochondrial membrane potential of nerve cells, protecting mitochondrial functions and increasing the ATP level in nerve cells. The pharmaceutical composition is good ineffect of preventing and / or treating neurodegenerative diseases, is small in side effect and is capable of effectively increasing the survival rate of nerve cells, effectively protecting mitochondrialmembrane potential of the nerve cells and effectively protecting the energy metabolism level of the nerve cells.

The invention discloses a preparation method of a compound PGHG in a medicine for treating parkinson's disease. The method comprises the following steps: performing ultrasonic extraction on Penthorumchinense Pursh. stem dry powder by using 70 percent of ethanol (1: 25), sequentially performing extraction by using petroleum ether and ethyl acetate to obtain extracting solutions; performing decompressing concentration and lyophilization on the extracting solutions to obtain Penthorum chinense Pursh. polyphenol fragments (PSE); separating the PSE through high-speed countercurrent chromatographyto obtain flow fractions A and B; further purifying the flow fraction A by adopting a preparative HPLC (High Performance Liquid Chromatography); manually collecting effluent liquid according to a chromatographic peak; performing decompressing concentration to obtain a monomer compound of which the purity is up to 99 percent; and the monomer compound is identified as PGHG through mass spectrometryand nuclear magnetic resonance spectroscopy. Due to the PSE and the PGHG, reduction of ATP level of 6-hydroxydopamine induced SH-SY5Y cells can be obviously suppressed, and the cell activity is improved. The PGHG can modulate and control expression of apoptosis protein and inflammatory protein through activating Nrf2 / HO-1 antioxidant pathway, and neuroprotection has an obvious effect on preventionand treatment of the parkinson's disease.

The invention belongs to the technical field of ganoderma spore compositions, and discloses a preparation method of a ganoderma spore composition for treating an Alzheimer disease. The preparation method comprises the following steps of picking fresh ganoderma spores, removing impurities and no-medicinal parts of the fresh ganoderma spores, the cleaning the fresh ganoderma spores, removing dust onthe upper parts of the ganoderma spores, and drying the fresh ganoderma spores; putting the dried ganoderma spores into a low temperature supersonic speed airflow energy grender to conduct grinding treatment, and ganoderma spore powder is formed; and taking the dried ganoderma spore powder, and through a 120 mesh screen, removing impurities. According to the ganoderma spore composition, the production technology is simple, operation is convenient, the ROS levels in blood platelets of an AD patient can be reduced by taking the ganoderma spore composition, plasma Abeta42 of the AD patient can be stabilized at a certain level, influences on the ATP levels of the blood platelets, mitochondrion COX activity of the blood platelets and the LEH level of the plasma of the AD patient are not generated, and swelling of mitochondrial of the blood platelets of the AD patient can be relaxed certainly.

The invention discloses application of sirtuin2 protein for improving mitochondrial functions and an action mechanism, which belong to the technical field of biology. The rhodotorula glutinis sirtuin2gene with the functions of reconstructing a mitochondrial network and improving the phenotype of mammalian senescent cells is recombined and expressed in mammalian cells. Experimental results show that the expression levels of fusion proteins Mfn1, Mfn2 and the division protein Drp1 can be improved, the SA-beta-gal activity level of mammalian cells is reduced, the expression level of CK19 and beta1 integrin is enhanced, the intracellular ROS level is reduced, the intracellular ATP level is obviously improved, the mitochondrial morphology is improved, the mitochondrial network is improved, theanti-aging capability of the cells is improved, and a new strategy is provided for treating mitochondrial dysfunction and preventing aging by using the sirtuin2 protein.

The invention relates to a sugar alcohol phosphate thiazolidine-4-carboxy compound with the structural formula as the specification. The compound is formed by integrating three groups and can release cysteine and ribose phosphate after being absorbed in vivo. Cysteine can be used for increasing the concentration of glutathione (GSH) in cells, improving the oxidation resistance of the cells and improving the inflammation diminishing and detoxifying capabilities of a human body from inside to outside. Ribose phosphate can be used for replenishing the energy loss caused by wounds or strenuous exercise while rapidly and effectively improving the ATP (Adenosine Triphosphate) level in tissues. Bodybuilding and brain-strengthening effects can be synchronously realized through the combination of carboxylate and phosphate groups and different trace elements.

The invention relates to applications of inhibition of Dcf1 gene expression in preparing drugs used for treating obesity. According to the invention, behavior tests of wild type mice (as a reference) and dcf1 knock-out mice are carried out, it is detected that the weight and food intake of mice are reduced because of dcf1 deletion, and NPY protein down-regulation is detected in Westernblotting and immunohistochemical detection, so that it is confirmed that dcf1 is at the upstream of NPY. ATP kit is used for detecting that after dcf1 knockout, mice hypothalamus tissue and primary culture cell ATP level increases. Expression of dcf1 and expression of NPY in 293T cells are both capable of reducing cell ATP level, so that dcf1 possesses an important effect in energy balance, and a novel method used for treating obesity is provided.

The invention relates to a preparation method of a sugar alcohol phosphate thiazolidine-4-carboxy compound with the structural formula as the specification. The compound is formed by integrating three groups and can release cysteine and ribose phosphate after being absorbed in vivo. Cysteine can be used for increasing the concentration of glutathione (GSH) in cells, improving the oxidation resistance of the cells and improving the inflammation diminishing and detoxifying capabilities of a human body from inside to outside. Ribose phosphate can be used for replenishing the energy loss caused by wounds or strenuous exercise while rapidly and effectively improving the ATP (Adenosine Triphosphate) level in tissues. Bodybuilding and brain-strengthening effects can be synchronously realized through the combination of carboxylate and phosphate groups and different trace elements.